Chitogenx Inc. Stock Analysis CHGX.CN
ChitogenX, Inc. is a clinical stage biotech company, which engages in the development of therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. The company is headquartered in Kirkland, Quebec. The company went IPO on 2017-10-10. The firm is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The firm is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Read More Chitogenx Inc (CHGX.CN) Chart
Key Statistics of Chitogenx Inc (CHGX.CN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.01Volume
120.00KP/E Ratio (TTM)
-52 Week Range
Market Cap
410.00KAvg. Volume
28.84KDividend Yield
-Financial Metrics & Statements of Chitogenx Inc (CHGX.CN)
FAQ's for Chitogenx Inc (CHGX.CN)
- According to Musaffa’s Shariah screening methodology, Chitogenx Inc (CHGX.CN) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.